Who are Non-selective NSAIDS's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cytotec, Bromfenac 0.09 % Ophthalmic Solution, Ropivacaine, Ketorolac and Adrenaline, Indomethacin suppository, Cefazolin and indomethacin, Ketorolac Ophthalmic Solution.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/non-selective-nsaids.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Non-selective NSAIDS — Competitive Intelligence Brief

Non-selective NSAIDS (Non-selective NSAIDS) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-selective NSAID. Area: Pain Management, Rheumatology, Cardiovascular.

marketed Non-selective NSAID COX-1 and COX-2 Pain Management, Rheumatology, Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Non-selective NSAIDS (Non-selective NSAIDS) — Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Non-selective NSAIDs inhibit both COX-1 and COX-2 enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Non-selective NSAIDS TARGET	Non-selective NSAIDS	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Non-selective NSAID	COX-1 and COX-2
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
Bromfenac 0.09 % Ophthalmic Solution	Bromfenac 0.09 % Ophthalmic Solution	Azienda USL Reggio Emilia - IRCCS	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Ropivacaine, Ketorolac and Adrenaline	Ropivacaine, Ketorolac and Adrenaline	University of Aarhus	marketed	Local anesthetic combination with NSAID and vasopressor	Voltage-gated sodium channels (ropivacaine); COX-1 and COX-2 (ketorolac); alpha and beta adrenergic receptors (adrenaline)
Indomethacin suppository	Indomethacin suppository	Azienda USL Reggio Emilia - IRCCS	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Cefazolin and indomethacin	Cefazolin and indomethacin	Thomas Jefferson University	marketed	Beta-lactam antibiotic + NSAID combination	Bacterial penicillin-binding proteins (cefazolin); COX-1 and COX-2 (indomethacin)
Ketorolac Ophthalmic Solution	Ketorolac Ophthalmic Solution	Bausch & Lomb Incorporated	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-selective NSAID class)

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Non-selective NSAIDS — Competitive Intelligence Brief. https://druglandscape.com/ci/non-selective-nsaids. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab